The American Society of Hematology (ASH) meeting is in full swing, and Day 2 brought some exciting news. Fulcrum Therapeutics presented a study suggesting that a higher dose of their experimental pill for sickle cell disease could be more effective at inducing an alternative form of hemoglobin. This development raises hopes for a simpler and more effective treatment for this debilitating disease.
Unfortunately, the rest of the information in this article is exclusive to STAT+ subscribers. If you want to unlock the full story and access daily coverage and analysis of the biotech sector, you can subscribe to STAT+.
The authors of this article include Adam Feuerstein, a senior writer and biotech columnist known for his insightful reporting on drug development and biotechnology. He is also a co-host of the popular biotech podcast, The Readout Loud. Damian Garde, another author of this piece, is a seasoned reporter covering the global drug industry and contributing to STAT’s industry-leading events. Angus Chen, the third author, specializes in covering all aspects related to cancer, including drugs, policy, science, and equity. His work has been recognized with prestigious awards in the field of cancer journalism.
Stay tuned for more updates from the ASH meeting and other important developments in the biotech sector by subscribing to STAT+.
